|Molecular mass||70.000 Da|
|Plasma concentration||0.07 g/l|
|Normal range||70 - 120% or 0.7 - 1.2 E/ml|
The plasmin inhibitor is the most important inhibitor of plasmin and therefore of great importance for the regulation of fibrinolysis. Plasmin inhibitor immediately binds free plasmin while fibrin-bound plasmin is not inhibited. In this way, the activity of the plasmin is localized to the fibrin clot and the danger of cleavage of other proteins by the unspecific protease plasmin is eliminated.
Hereditary deficiency is correlated with a massive bleeding tendency, comparable to severe haemophilia. An acquired deficiency occurs following hepatic disease, acute promyelocyte leukaemia, major surgery and DIC. Lysis therapy is correlated with an increased fibrinolytic activity, following a consumption of plasmin inhibitor.
- Suspected increased fibrinolysis as cause of a bleeding tendency
- A plasmin inhibitor deficiency during lysis therapy also points to a plasminemia
- Friberger P. Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems. Scand J Clin Lab Invest 42, suppl 162, 1982.
- Wiman B. Human α2-Antiplasmin. IN Laurent, L. (ed). Methods in enzymology. Proteolytic enzymes, Part C. Academic Press New York 80, 395-408, 1981.
- Hattey E et al. Plasmin-?2-Antiplasmin complexes (plasmin-plasmin inhibitor complexes) In: Jespersen J, Bertina RM, Haverkate F. (eds.). Laboratory Techniques In Thrombosis: A Manual. 2nd revised edition of ECAT Assay Procedures. Kluwer Academic Publishers, 1999.
- Kluft C, Meijer P. Plasmin inhibitor activity (previously ?2-antiplasmin) In: Jespersen J, Bertina RM, Haverkate F (eds.). Laboratory Techniques In Thrombosis: A Manual. 2nd revised edition of ECAT Assay Procedures. Kluwer Academic Publishers, 1999.
- Billing Clason S et.al. A novel method, COAMATIC® Plasmin Inhibitor, for the specific determination of Plasmin Inhibitor activity in plasma. Fibrinolysis 10, suppl.2, 165-167, 1996.
- Saupe SM, Steinmetzer T. A new strategy for the development of highly potent and selective plasmin inhibitors. J Med Chem. Feb 9, 55(3), 1171-80, 2012.